Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,489
  • Shares Outstanding, K 48,643
  • Annual Sales, $ 5,490 K
  • Annual Income, $ -50,730 K
  • 60-Month Beta 1.96
  • Price/Sales 5.01
  • Price/Cash Flow N/A
  • Price/Book 1.27
Trade CUE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.97
  • Most Recent Earnings $-0.20 on 08/14/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -42.53%)
  • Historical Volatility 91.80%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 535.51% on 04/18/24
  • IV Low 0.00% on 09/19/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,016
  • Open Int (30-Day) 1,990

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.27
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5167 +1.41%
on 09/20/24
1.0000 -47.60%
on 08/21/24
-0.3400 (-39.35%)
since 08/20/24
3-Month
0.5167 +1.41%
on 09/20/24
1.5800 -66.84%
on 06/26/24
-0.7760 (-59.69%)
since 06/20/24
52-Week
0.5167 +1.41%
on 09/20/24
3.2491 -83.87%
on 12/08/23
-1.8060 (-77.51%)
since 09/20/23

Most Recent Stories

More News
Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.5240 (-7.26%)
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.5240 (-7.26%)
Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.5240 (-7.26%)
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.5240 (-7.26%)
Cue Biopharma Reports First Quarter 2022 Financial Results

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 0.5240 (-7.26%)
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in...

CUE : 0.5240 (-7.26%)
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.5240 (-7.26%)
Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.5240 (-7.26%)
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.5240 (-7.26%)
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel...

CUE : 0.5240 (-7.26%)

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.6104
2nd Resistance Point 0.5902
1st Resistance Point 0.5571
Last Price 0.5240
1st Support Level 0.5038
2nd Support Level 0.4836
3rd Support Level 0.4505

See More

52-Week High 3.2491
Fibonacci 61.8% 2.2053
Fibonacci 50% 1.8829
Fibonacci 38.2% 1.5605
Last Price 0.5240
52-Week Low 0.5167

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar